Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Effectiveness and Safety of Polatuzumab Vedotin-Based Therapy for Diffuse Large B-Cell Lymphoma: Real-Life Experience from China

Xi Chen, Haifeng Yu, Cong Li, Jieyu Xu, Tao Lei, Shuiyun Han, Shuailing Peng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 7782.

https://doi.org/10.1182/blood-2024-207832

Published: 2024

Journal Articles

Novel Combination Regimen Brentuximab Vedotin-Bege Achieves Remarkable Efficacy in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Xi Chen, Huilin Peng, Haifeng Yu, Cong Li, Tao Lei, Shuiyun Han, Shuailing Peng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2024-207627

Published: 2024

Journal Articles

The Surface-Exposed Nuclear Speckle Protein SRRM2 Confers a Novel Target Molecule for the Immunotherapy of Acute Myeloid Leukemia

Wanqiu Zhang, Zhimai Gao, Kathrin Gärtner, Huiping Wang, Fan Wu, Jinjing Guo, Yingwei Li, Zijian Li, Lietao Li, Cong Li, Xue Liang, Hao Xiao, Zhimin Zhai

Blood (2024) 144 (Supplement 1): 7171.

https://doi.org/10.1182/blood-2024-201180

Published: 2024

Journal Articles

Novel SRRM2-Targeted CAR-T Therapy Induces Rapid Remission in a Relapsed/Refractory Multiple Myeloma Patient

Zhitao Wang, Zhimai Gao, Fan Wu, Huiping Wang, Jinjing Guo, Yingwei Li, Zijian Li, Kathrin Gärtner, Lietao Li, Cong Li, Xue Liang, Hao Xiao, Zhimin Zhai

Blood (2024) 144 (Supplement 1): 7094.

https://doi.org/10.1182/blood-2024-201947

Published: 2024

Journal Articles

Vincristine Overcomes Cytarabine Resistance in Acute Myeloid Leukemia By Suppression of ARHGAP18-Mediated Cellular Senescence

Xiyang Ren, Haotian Yan, Mei Zhou, Fan Wu, Qing Zhang, Yangyang Ding, Qian Li, Huiping Wang, Caixian Xu, Jiyu Wang, Cong Li, Wanqiu Zhang, Linlin Liu, Ruotong Chen, Yi Dong, Wenjie Dai, Zhimin Zhai, Qianshan Tao

Blood (2024) 144 (Supplement 1): 2754.

https://doi.org/10.1182/blood-2024-205440

Published: 2024

Journal Articles

Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Meijuan Wu, Xi Chen, Jialiang Lu, Weihao Zhuang, Chang He, Cong Li, Haifeng Yu, Tao Lei, Xiaowu Dong, Jianpeng Sheng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2024-203388

Published: 2024

Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Blood (2024) 144 (4): 359–367.

https://doi.org/10.1182/blood.2024024371

Published: 2024

Includes: Supplemental data

Journal Articles

A Prospective, Exploratory, Phase II Study of the Xpo-1 Inhibitor Selinexor in Combination with RCHOP in Double/Triple-Hit Large B-Cell Lymphoma

Cong Li, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6242.

https://doi.org/10.1182/blood-2023-184634

Published: 2023

Journal Articles

Real-World Analysis of Obinutuzumab-Based Immunochemotherapy in Follicular Lymphoma in Chinese Population

Xi Chen, Jieyu Xu, Haifeng Yu, Tao Lei, Cong Li, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6311.

https://doi.org/10.1182/blood-2023-189282

Published: 2023

Journal Articles

Updated Results of a Prospective Study: Rituximab and Lenalidomide Plus Chidamide (RLC) for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

Cong Li, Huixian HU, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6221.

https://doi.org/10.1182/blood-2023-184830

Published: 2023

Journal Articles

TGF-β Inhibitor SD-208 Enhances the Anti-Tumor Efficacy of CD19 CAR-T Cells through a Reduction of CAR-Treg in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Cong Li, Huiping Wang, Xue Liang, Ying Pan, Jiyu Wang, Qiang Hong, Qianshan Tao, Yanghua Tian, Zhimin Zhai

Blood (2023) 142 (Supplement 1): 6831.

https://doi.org/10.1182/blood-2023-184401

Published: 2023

Journal Articles

PD-1 Blockade Combined with R-CHOP in Patients with Newly Diagnosed EBV-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Xi Chen, Yingying Chen, Tao Lei, Haifeng Yu, Cong Li, Yongwei Hong, Haiyan Yang

Blood (2023) 142 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2023-182685

Published: 2023

Journal Articles

Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive B-Cell Lymphoma

Cong Li, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang

Blood (2023) 142 (Supplement 1): 6227.

https://doi.org/10.1182/blood-2023-184694

Published: 2023

Journal Articles

Gp350-Targeted CAR-T Therapy in EBV-Positive NK/T-Cell Lymphoma: Pre-Clinical Development of gp350CAR-T

Zhimai Gao, Fan Wu, Cong Li, Huiping Wang, Xue Liang, Zhimin Zhai

Blood (2023) 142 (Supplement 1): 4810.

https://doi.org/10.1182/blood-2023-184785

Published: 2023

Journal Articles

Ixazomib Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation: A Single-Arm, Open-Label Study

Weijun Fu, Juan Du, Lu Zhong, Lijuan Chen, Jian Li, Donghua Zhang, Jianqing Mi, Yan Liu, Sheng Wu, Richard Labotka, Cong Li, Wenhan Jiang, Wenming Chen

Blood (2023) 142 (Supplement 1): 6735.

https://doi.org/10.1182/blood-2023-181444

Published: 2023

Journal Articles

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Blood (2023) 141 (6): 579–591.

https://doi.org/10.1182/blood.2022016782

Published: 2023

Includes: Supplemental data

Journal Articles

Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients

Martin F. Kaiser, Pieter Sonneveld, David Cairns, Marc S Raab, Alessandra Larocca, Sarah R Brown, Marc-A. Baertsch, Cong Li, Pellegrino Musto, Kwee Yong, Elias K Mai, Andrea Capra, Gordon Cook, Hartmut Goldschmidt, Mario Boccadoro, Graham Jackson, Niels Weinhold, Francesca Gay

Blood (2022) 140 (Supplement 1): 1556–1558.

https://doi.org/10.1182/blood-2022-160130

Published: 2022

Journal Articles

Rituximab and Lenalidomide Plus Chidamide Can be an Effective Chemotherapy Regimen for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

Cong Li, Tao Lei, Haifeng Yu, Xi Chen, Shuiyun Han, Shuailing Peng, Haiyan Yang

Blood (2022) 140 (Supplement 1): 3689–3690.

https://doi.org/10.1182/blood-2022-166370

Published: 2022

Journal Articles

"Gentle Initiation” Rituximab, Lenalidomide and Zanubrutinib Chemo-Free Regimen Followed By Immunochemotherapy for Elderly/Frail Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Investigator Initiated, Single Arm, Phase 2 Trial

Xi Chen, Tao Lei, Haifeng Yu, Cong Li, Shuiyun Han, Shuailing Peng, Haiyan Yang

Blood (2022) 140 (Supplement 1): 9452–9453.

https://doi.org/10.1182/blood-2022-164486

Published: 2022

Journal Articles

The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study

Haiyan Yang, Cong Li

Blood (2021) 138 (Supplement 1): 2482.

https://doi.org/10.1182/blood-2021-149541

Published: 2021

NARROW

Effectiveness and Safety of Polatuzumab Vedotin-Based Therapy for Diffuse Large B-Cell Lymphoma: Real-Life Experience from China

Novel Combination Regimen Brentuximab Vedotin-Bege Achieves Remarkable Efficacy in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

The Surface-Exposed Nuclear Speckle Protein SRRM2 Confers a Novel Target Molecule for the Immunotherapy of Acute Myeloid Leukemia

Novel SRRM2-Targeted CAR-T Therapy Induces Rapid Remission in a Relapsed/Refractory Multiple Myeloma Patient

Vincristine Overcomes Cytarabine Resistance in Acute Myeloid Leukemia By Suppression of ARHGAP18-Mediated Cellular Senescence

Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

A Prospective, Exploratory, Phase II Study of the Xpo-1 Inhibitor Selinexor in Combination with RCHOP in Double/Triple-Hit Large B-Cell Lymphoma

Real-World Analysis of Obinutuzumab-Based Immunochemotherapy in Follicular Lymphoma in Chinese Population

Updated Results of a Prospective Study: Rituximab and Lenalidomide Plus Chidamide (RLC) for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

TGF-β Inhibitor SD-208 Enhances the Anti-Tumor Efficacy of CD19 CAR-T Cells through a Reduction of CAR-Treg in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

PD-1 Blockade Combined with R-CHOP in Patients with Newly Diagnosed EBV-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive B-Cell Lymphoma

Gp350-Targeted CAR-T Therapy in EBV-Positive NK/T-Cell Lymphoma: Pre-Clinical Development of gp350CAR-T

Ixazomib Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation: A Single-Arm, Open-Label Study

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients

Rituximab and Lenalidomide Plus Chidamide Can be an Effective Chemotherapy Regimen for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

"Gentle Initiation” Rituximab, Lenalidomide and Zanubrutinib Chemo-Free Regimen Followed By Immunochemotherapy for Elderly/Frail Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Investigator Initiated, Single Arm, Phase 2 Trial

The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only